Albireo Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for sharp weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Albireo Pharma (ALBO) Misses Q1 EPS by 7c, Revenues Miss
May 9, 2019 7:40 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($1.39), $0.07 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $970 thousand.
For Albireo, 2019 is focused on advancing toward potential approval and launch of odevixibat in its first... More
